|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
 |
3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. Although vaccines can be effective, successful vaccine development remains challenging for many pathogens. Moreover, pathogens often escape treatment by rapidly mutating to acquire drug resistance. In the case of viruses, most traditional drugs aim at the pathogen itself and possess a narrow spectrum of activity due to viral diversity. Viruses hijack host pathways to infect cells. 3-V Biosciences targets these host pathways, providing a roadblock to viral infection and replication. Our innovative strategy offers three major advantages over the traditional pathogen-directed approach: Low likelihood for resistance - because viruses are unlikely to overcome their dependency on host targets Broad spectrum activity - allows effective treatment of all circulating strains of a specific virus with the potential to treat multiple unrelated viruses that require the same host pathway Numerous host targets - enable selection of drug targets having optimal efficacy and safety profiles Viral illnesses are typically treated using a “One Drug, One Bug” approach. However, multiple unrelated viruses can cause the same clinical syndrome, complicating the diagnosis and treatment of patients. 3-V Biosciences’ agents allow the potential for a “One Drug, Multiple Bugs” antiviral therapeutic paradigm, analogous to antibiotic treatment of most bacterial infections. |
||
Website developed by |
© 2009 3-V Biosciences, Inc. | ||
